D75.829

Clinical Causes: Heparin therapy: The primary trigger is the use of heparin, which may be administered during surgeries, dialysis, or treatment of blood clots. Immune response: The body may produce antibodies against complexes of heparin and platelet factor 4 (PF4), activating platelets and causing their removal from circulation. Genetic predisposition: Some individuals may have genetic factors making them more susceptible to developing HIT.

Key Symptoms: Drop in platelet count: A significant decrease in the number of platelets, often observed within 5 to 14 days of heparin treatment. Formation of blood clots: These can occur in veins or arteries, leading to deep vein thrombosis, pulmonary embolism, or other clot-related complications. Skin reactions: Redness, swelling, or skin necrosis at heparin injection sites. Bleeding: Unusual bleeding or bruising, especially if the platelet count becomes dangerously low. Other signs: Shortness of breath, chest pain, or neurological symptoms if blood clots affect different organs.

Diagnosis Path: Diagnosis involves a combination of clinical assessment and laboratory testing. Physicians typically consider recent heparin use, platelet counts, and signs of thrombosis. Specific blood tests that support diagnosis include enzyme-linked immunosorbent assay (ELISA) to detect antibodies against PF4-heparin complexes and confirmatory functional assays like the serotonin release assay (SRA). Imaging studies might be necessary if blood clots are suspected.

Treatment Protocols: Managing HIT requires immediate discontinuation of all heparin products. Alternative anticoagulant therapies such as argatroban or danaparoid are often used to prevent clot formation. Monitoring of platelet counts and clinical signs is essential throughout treatment. In some cases, plasmapheresis may be employed to remove harmful antibodies. Patients should be carefully evaluated before any future use of heparin or related medications, and comprehensive follow-up is vital to prevent recurrence.